Remove 2022 Remove Hospital Remove Imaging Modalities Remove Nuclear Medicine
article thumbnail

Imaging Market Share Analysis Shows 28% of Image Interpretation Performed by Non-Radiologists

Imaging Technology

of all imaging studies for Medicare fee-for-service beneficiaries in 2022, with the remaining 27.9% According to a written study summary released by HPI, market share varied by imaging modality; radiologists interpreted 97.3% of nuclear medicine (NM), and 33.9% performed by other types of clinicians.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

Thomas Hope, MD, a radiologist and nuclear medicine physician at the University of California, San Francisco (UCSF), said that approval of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand has driven a marked interest and excitement about theranostics and radioligand therapies (RLT). Hope added. Hope added.